Skyai, Inc. annual report, FY2024

Business Context and Reporting Period

Company: Sharps Technology, Inc. (STSS)

Filing Type: Form 10-K (Annual Report)

Reporting Period: Fiscal year ended December 31, 2024

Business Overview: Sharps is a pre-revenue medical device company developing patented smart-safety syringes (Securegard and Sologard lines) and prefillable polymer syringes. The company operates a 41,000-square-foot manufacturing facility in Hungary and maintains corporate offices in Melville, New York. As of the filing date, the company has not generated any product revenue and is focused on commercialization, inventory buildup, and securing manufacturing capacity.

Key Financial Metrics

Metric 2024 2023
Revenue $0 $0
Net Loss $(9,296,202) $(9,841,638)
Operating Expenses $9,626,710 $10,126,650
Cash and Cash Equivalents (Year End) $864,041 $3,012,908
Working Capital $(2,011,678) Deficit $1,145,569 Surplus
Total Assets $7,313,748 $11,789,268
Accumulated Deficit $(34,445,206) $(25,149,004)

Debt and Liquidity: As of December 31, 2024, the company held a Senior Secured Note payable of approximately $3.76 million (net of discount). The company reported a working capital deficit of $2.0 million. However, subsequent to year-end, the company closed a $20 million offering (net proceeds ~$18.2 million) in January 2025, using $4.2 million to repay outstanding notes, returning the company to a debt-free status.

Material Changes vs. Prior Period

  • Net Loss Reduction: Net loss decreased by approximately $545,000 (6%) compared to 2023, primarily driven by a significant non-cash Fair Market Value (FMV) gain on warrant liabilities of $3.0 million in 2024, compared to $169,000 in 2023.
  • Asset Impairment: Research and Development expenses included a $1.77 million impairment charge in 2024 related to assembly machines, compared to a $560,000 impairment in 2023.
  • Other Expenses: Other expenses increased by $1.0 million in 2024 due to the forfeiture of a $1 million escrow deposit related to a terminated asset acquisition agreement (InjectEZ).
  • Stock Structure: The company effected a 1-for-22 reverse stock split in October 2024 to regain compliance with Nasdaq listing rules.

Guidance, Outlook, and Risks

Outlook and Guidance: Management anticipates a transition to revenue in the second half of 2025, contingent on successful execution of manufacturing plans and qualification approvals. The company has secured a supply agreement with Stericare Solutions for 520 million units of Sologard syringes (expected revenue >$50 million) and a sales agreement with a European distributor. The recent $20 million financing is intended to fund production expansion in Hungary and working capital.

Key Risks and Contingencies:

  • Going Concern: The auditor has raised substantial doubt about the company's ability to continue as a going concern based on the December 31, 2024 financial position, citing a history of losses and lack of revenue. This was mitigated by the January 2025 financing.
  • Nasdaq Delisting: In March 2025, the company received notice of non-compliance with the Nasdaq minimum bid price requirement ($1.00). The company is not eligible for a standard compliance period due to a recent reverse split and has requested a hearing to appeal the delisting determination.
  • Legal Proceedings: The company is involved in litigation with former co-founder Barry Berler (claims totaling ~$456,000 plus arbitration claims of $500,000) and supplier Plastomold Industries (claims of $1.76 million). The company intends to defend these vigorously.
  • Commercialization Delays: The commercialization of the "Provensa" product line has been delayed indefinitely pending further capital investment.

Investor Verification Checklist

  • Capital Adequacy: Verify the final closing details and net proceeds of the January 2025 $20 million offering to confirm the debt repayment and current cash runway.
  • Nasdaq Status: Monitor the outcome of the Nasdaq hearing regarding the minimum bid price deficiency and potential delisting.
  • Revenue Realization: Track the qualification status of Securegard and Sologard products with EU and US partners to validate the projected 2025 revenue timeline.
  • Legal Exposure: Review the status of the Berler and Plastomold lawsuits to assess potential financial liabilities or operational disruptions.
  • Asset Acquisition: Confirm the status of the InjectEZ asset purchase agreement, given the previous forfeiture of the $1 million deposit.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.